Icosapent ethyl (VASCEPA) as treatment for post-acute sequelae of SARS CoV-2 (PASC) vaccine induced injury and infection.

Objectives: As the COVID-19 pandemic continues, a prolonged post-infectious syndrome or "long COVID" has been reported. This is a multi-organ post viral syndrome that persists well after infection. Currently, there is no available treatment.